UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 21.484

Sortiert nach

European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab

Business Wire, 2024-06-21

2024

Link zum Volltext

Verfügbarkeit prüfen

FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma

Business Wire, 2024-06-17

2024

Link zum Volltext

Verfügbarkeit prüfen

IMFINZI (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

Business Wire, 2024-06-17

2024

Link zum Volltext

Verfügbarkeit prüfen

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

Business Wire, 2024-06-14

2024

Link zum Volltext

Verfügbarkeit prüfen

TALVEY (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

PR newswire, 2024-06-14

2024

Link zum Volltext

Verfügbarkeit prüfen

U.S. Food and Drug Administration Approves Augtyro (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Business Wire, 2024-06-13

2024

Link zum Volltext

Verfügbarkeit prüfen

U.S. Food and Drug Administration Approves Augtyro[TM] , for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Business Wire, 2024-06-13

2024

Link zum Volltext

Verfügbarkeit prüfen

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

Business Wire, 2024-06-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Jemperli rectal cancer

Business Wire, 2024-06-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

Business Wire, 2024-06-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care

PR newswire, 2024-06-02

2024

Link zum Volltext

Verfügbarkeit prüfen

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

Business Wire, 2024-05-31

2024

Link zum Volltext

Verfügbarkeit prüfen

Gilead Provides Update on Phase 3 TROPiCS-04 Study

Business Wire, 2024-05-30

2024

Link zum Volltext

Verfügbarkeit prüfen

FDA Grants Priority Review to Merck's Application for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Business Wire, 2024-05-29

2024

Link zum Volltext

Verfügbarkeit prüfen

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Business Wire, 2024-05-29

2024

Link zum Volltext

Verfügbarkeit prüfen

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Business Wire, 2024-05-28

2024

Link zum Volltext

Verfügbarkeit prüfen

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival

Business Wire, 2024-05-28

2024

Link zum Volltext

Verfügbarkeit prüfen

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

PR newswire, 2024-05-28

2024

Link zum Volltext

Verfügbarkeit prüfen

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant at the ASCO 2024 Annual Meeting

PR newswire, 2024-05-24

2024

Link zum Volltext

Verfügbarkeit prüfen

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

PR newswire, 2024-05-24

2024

Link zum Volltext

Verfügbarkeit prüfen

BRUKINSA Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

Business Wire, 2024-05-24

2024

Link zum Volltext

Verfügbarkeit prüfen

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant at the ASCO 2024 Annual Meeting

Business Wire, 2024-05-23

2024

Link zum Volltext

Verfügbarkeit prüfen

Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

PR newswire, 2024-05-23

2024

Link zum Volltext

Verfügbarkeit prüfen

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

Business Wire, 2024-05-23

2024

Link zum Volltext

Verfügbarkeit prüfen

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

Business Wire, 2024-05-21

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 21.484

Suche als RSS-Feed

Aktive Filter

SpracheAfrikaans

PublikationsformArtikel

PublikationsformNewsletter-Artikel

PublikationsformBerichte

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(276)
Mit Volltextzugriff
(5.700)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

ProQuest Dissertations & Theses A&I
(12.598)
Ebook Central Perpetual and DDA
(6.418)
eBooks on EBSCOhost
(6.068)
Nexis
(1.838)
ScienceDirect eBooks
(1.449)
Wiley Online Library All Obooks
(1.165)
Taylor & Francis eBooks A-Z
(1.047)
SpringerLink Series
(227)
Ingenta
(155)
MEDLINE
(129)
EZB Electronic Journals Library
(76)
NUS Single-Journal Subscriptions
(56)
EBSCOhost Business Source Ultimate
(50)
De Gruyter eBooks
(33)
Journals@Ovid Complete
(23)
SAGE Publications
(20)
Elsevier ScienceDirect Journals
(17)
Wiley Online Library - AutoHoldings Journals
(12)
Sociological Abstracts
(12)
IngentaConnect Journals
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab

FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma

IMFINZI (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

TALVEY (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

U.S. Food and Drug Administration Approves Augtyro (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

U.S. Food and Drug Administration Approves Augtyro[TM] , for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

Jemperli rectal cancer

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

Gilead Provides Update on Phase 3 TROPiCS-04 Study

FDA Grants Priority Review to Merck's Application for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant at the ASCO 2024 Annual Meeting

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

BRUKINSA Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant at the ASCO 2024 Annual Meeting

Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

Aktive Filter

Suchergebnisse filtern